DENVER–(BUSINESS WIRE)–BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced its acquisition of AlertWatch®, an FDA cleared and clinically proven patient monitoring solution. AlertWatch uniquely provides robust integration, data analysis, and patented intuitive display of contextual patient data for more efficient and actionable clinical decisions. As part of the recently announced strategic partnership with Medtronic, its patient monitoring business will distribute AlertWatch to hospitals across the United States as a new offering in its HealthCast™ portfolio.

“The addition of AlertWatch provides healthcare providers with comprehensive continuous monitoring solutions and an accelerated path from adoption to widespread use,” said James Mault, MD, Founder and CEO of BioIntelliSense. “Patented AlertWatch multi-parameter interface displays and analyzes vital signs data from hospital patients, electronic medical record (EMR), laboratory systems, and BioIntelliSense medical-grade wearable devices to provide clinical intelligence across parameters care and acuity levels.

Hospitals nationwide are seeking enterprise-grade platforms that optimize labor-intensive processes through data capture automation combined with scalable exception management and clinical insights from the home hospital. Over the past decade, AlertWatch has obtained four FDA 510(k) clearances for its specialty product offerings for the operating room, intensive care unit, and labor and delivery unit. AlertWatch also monitors patients in general care wards – and now, at home.

The AlertWatch centralized triage dashboard aggregates data and provides clinicians with a composite view of patient vital signs trends, while simultaneously performing advanced analytics and alerts, for proactive clinical decisions. The AlertWatch system has been used to support over one million surgeries and over 25,000 births. The AlertWatch operating room solution, when comparing users to non-users, was associated with a one-day reduction in postoperative length of stay (LOS) and a $3,603 reduction in fees consultation.1

“By joining forces with BioIntelliSense, we are excited to significantly expand the reach and adoption of our world-class clinical decision support solution,” said Professor Kevin Tremper, MD, PhD, Founder and President. from AlertWatch. “The benefits of workflow automation not only help reduce hospital stays and costs, but also help clinicians and nurses by alerting them with highly actionable insights that prioritize and personalize patient care.”

The BioIntelliSense and AlertWatch platforms are interoperable solutions with extensive third-party and EMR system integration and data exchange capabilities. BioIntelliSense remains committed to an ecosystem approach that provides the flexibility, security, and scalability to meet our customers’ patient monitoring needs.

“I’m excited to see our partnership with BioIntelliSense grow so that together we can help more patients in more places,” said Frank Chan, president of the Patient Monitoring business, part of the portfolio of medical surgery at Medtronic. “Adding the AlertWatch system to our HealthCast™ portfolio of connectivity and remote monitoring solutions reinforces our commitment to patient safety and enables workflow efficiencies for our customers when monitoring patients at the hospital. hospital and at home.

AlertWatch (Booth #2909) and Medtronic (Booth #3228) will be demonstrating the BioIntelliSense BioButton and AlertWatch solutions at the 2022 American Society of Anesthesiologists (ASA) ANESTHESIOLOGY Annual Meeting.

For the latest news and information on how BioIntelliSense simplifies early detection™ with medical-grade wearable technology and cost-effective data services, visit our website at biointelliSense.com and follow BioIntelliSense on Twitter and LinkedIn.

Reference:

1. Kheterpal S, Shanks A, Tremper KK. Impact of a new multiparameter decision support system on intraoperative care processes and postoperative outcomes. Anesthesiology. 2018;128(2):272-282.

ABOUT BIOINTELLISENSE

BioIntelliSense ushers in a new era of continuous health monitoring and clinical intelligence for remote patient monitoring (RPM). Its medical-grade data-as-a-service (DaaS) platform seamlessly captures multiparameter vital signs, physiological biometrics, and symptomatic events through an effortless patient experience. The medical grade BioButton® portable device simplifies remote monitoring and early detection. With the platform’s advanced analytics, clinicians have access to high-resolution patient trends and reports to enable medical-grade remote care from hospital to home.

Learn how BioIntelliSense is redefining remote patient monitoring with cost-effective, medical-grade data services by visiting our website at biointellisense.com. Follow BioIntelliSense on Twitter and LinkedIn for the latest news and information.